Cited by 57Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function

Open access
Milstein, Jean A., Elnabawi, Ahmed, Vinish, Monika, Swanson, Thomas, Enos, Jennifer K., Bailey, Aileen M., Kolb, Bryan, Frost, Douglas O.·2013·PLoS ONE

Abstract

Antipsychotic drugs are increasingly used in children and adolescents to treat a variety of psychiatric disorders. However, little is known about the long-term effects of early life antipsychotic drug treatment. Most antipsychotic drugs are potent antagonists or partial agonists of dopamine D2 receptors; atypical antipsychotic drugs also antagonize type 2A serotonin receptors. Dopamine and serotonin regulate many neurodevelopmental processes. Thus, early life antipsychotic drug treatment can, potentially, perturb these processes, causing long-term behavioral- and neurobiological impairments. Here, we treated adolescent, male rats with olanzapine on post-natal days 28-49. As adults, they exhibited impaired working memory, but normal spatial memory, as compared to vehicle-treated control rats. They also showed a deficit in extinction of fear conditioning. Measures of motor activity and skill, habituation to an open field, and affect were normal. In the orbital- and medial prefrontal cortices, parietal cortex, nucleus accumbens core and dentate gyrus, adolescent olanzapine treatment altered the developmental dynamics and mature values of dendritic spine density in a region-specific manner. Measures of motor activity and skill, habituation to an open field, and affect were normal. In the orbital- and medial prefrontal cortices, D1 binding was reduced and binding of GABA(A) receptors with open Cl(-) channels was increased. In medial prefrontal cortex, D2 binding was also increased. The persistence of these changes underscores the importance of improved understanding of the enduring sequelae of pediatric APD treatment as a basis for weighing the benefits and risks of adolescent antipsychotic drug therapy, especially prophylactic treatment in high risk, asymptomatic patients. The long-term changes in neurotransmitter receptor binding and neural circuitry induced by adolescent APD treatment may also cause enduring changes in behavioral- and neurobiological responses to other therapeutic- or illicit psychotropic drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0057308

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Milstein, J. A., Elnabawi, A., Vinish, M., Swanson, T., Enos, J. K., Bailey, A. M., Kolb, B., & Frost, D. O.
Affiliations
  • University of Maryland, Baltimore (US)
  • St. Mary's College of Maryland (US)
  • University of Lethbridge (CA)
Corresponding author
Frost, Douglas O.
Venue
PLoS ONE
Published
2013-02-20
Volume
8
Issue
2
Pages
e57308
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1972460604
Cited by
57
References
118
Citations by year
2026: 1 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 9 · 2015: 3 · 2014: 4 · 2013: 6
FWCI
5.20
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Open ULeth Scholarship (OPUS) (University of Lethbridge) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Canadian Institutes of Health Research
  • National Institute of Mental Health (MH07083)
  • National Institute of Neurological Disorders and Stroke (T32NS007375)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
olanzapine, antipsychotic effects, working memory impairment, fear extinction, dendritic spine density, prefrontal cortex, nucleus accumbens, dopamine D1 receptor, dopamine D2 receptor, GABAA receptor, serotonin receptors, brain development, long-term drug effects
MeSH terms
Olanzapine, Age Factors, Animals, Benzodiazepines, Dopamine, Extinction, Psychological, Male, Memory Disorders, Memory, Short-Term, Nucleus Accumbens, Receptors, GABA-A, Serotonin, Time, Antipsychotic Agents, Rats, Sprague-Dawley, Prefrontal Cortex, Receptors, Dopamine D2, Dentate Gyrus, Receptor, Serotonin, 5-HT2A, Dendritic Spines, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review